463 filings
10-Q
2024 Q1
LUMO
Lumos Pharma Inc
Quarterly report
15 May 24
4:05pm
8-K
LUMO
Lumos Pharma Inc
15 May 24
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
9:57am
10-K/A
2023 FY
LUMO
Lumos Pharma Inc
Annual report (amended)
22 Apr 24
4:30pm
8-K
LUMO
Lumos Pharma Inc
18 Apr 24
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
4:53pm
ARS
2023 FY
LUMO
Lumos Pharma Inc
15 Apr 24
Annual report to shareholders
4:32pm
DEFA14A
lapujms5 q6
12 Apr 24
Additional proxy soliciting materials
5:27pm
8-K
p2l5p9lv
20 Mar 24
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
4:27pm
8-K
rzi7iwc8yx8cj18y 7p
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
8-K
8hqdn6ngk cjhbtir2
4 Jan 24
Regulation FD Disclosure
4:34pm
8-K
ywyqjy89d h25mvh4vr7
15 Nov 23
Other Events
4:38pm
8-K
vr23ydvhafu4yaj2ie
7 Nov 23
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
4:42pm
8-K
2fncp 527a08mzoud
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
8-K
vbnd8niqy5frb as
26 Sep 23
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
4:34pm
8-K
v8o8i0
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
3t6v8vnx14x69w55
28 Jun 23
Lumos Pharma Announces Departure of Chief Medical Officer
4:26pm
8-K
u2sixkvb1qb0xk7ydrv
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm